1
|
Zhao L, Zheng Q, Zou Y, Wang Y, Wu Y, Liu X. Chitooligosaccharide Biguanidine Alleviates Liver Injury and Insulin Resistance in Type 2 Diabetic Rats. STARCH-STARKE 2019. [DOI: 10.1002/star.201900203] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Liyan Zhao
- School of Material Science and EngineeringTianjin Key Laboratory of Composite and Functional MaterialsTianjin University Tianjin 300350 China
| | - Qifang Zheng
- School of Material Science and EngineeringTianjin Key Laboratory of Composite and Functional MaterialsTianjin University Tianjin 300350 China
| | - Yalu Zou
- School of Material Science and EngineeringTianjin Key Laboratory of Composite and Functional MaterialsTianjin University Tianjin 300350 China
| | - Yuanyuan Wang
- School of Material Science and EngineeringTianjin Key Laboratory of Composite and Functional MaterialsTianjin University Tianjin 300350 China
| | - Yuntang Wu
- Department of Nutrition and Food ScienceSchool of Public HealthTianjin Medical University Tianjin 300070 China
| | - Xiaofei Liu
- School of Material Science and EngineeringTianjin Key Laboratory of Composite and Functional MaterialsTianjin University Tianjin 300350 China
| |
Collapse
|
2
|
Wei R, Hong T. Lineage Reprogramming: A Promising Road for Pancreatic β Cell Regeneration. Trends Endocrinol Metab 2016; 27:163-176. [PMID: 26811208 DOI: 10.1016/j.tem.2016.01.002] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 12/24/2015] [Accepted: 01/06/2016] [Indexed: 12/18/2022]
Abstract
Cell replacement therapy is a promising method to restore pancreatic β cell function and cure diabetes. Distantly related cells (fibroblasts, keratinocytes, and muscle cells) and developmentally related cells (hepatocytes, gastrointestinal, and pancreatic exocrine cells) have been successfully reprogrammed into β cells in vitro and in vivo. However, while some reprogrammed β cells bear similarities to bona fide β cells, others do not develop into fully functional β cells. Here we review various strategies currently used for β cell reprogramming, including ectopic expression of specific transcription factors associated with islet development, repression of maintenance factors of host cells, regulation of epigenetic modifications, and microenvironmental changes. Development of simple and efficient reprogramming methods is a key priority for developing fully functional β cells suitable for cell replacement therapy.
Collapse
Affiliation(s)
- Rui Wei
- Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing 100191, China
| | - Tianpei Hong
- Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing 100191, China.
| |
Collapse
|
3
|
Gu J, Li W, Xiao D, Wei S, Cui W, Chen W, Hu Y, Bi X, Kim Y, Li J, Du H, Zhang M, Chen L. Compound K, a final intestinal metabolite of ginsenosides, enhances insulin secretion in MIN6 pancreatic β-cells by upregulation of GLUT2. Fitoterapia 2013; 87:84-8. [PMID: 23558203 DOI: 10.1016/j.fitote.2013.03.020] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2013] [Revised: 03/19/2013] [Accepted: 03/24/2013] [Indexed: 01/07/2023]
Abstract
Compound K (CK) is a final intestinal metabolite of protopanaxadiol-type ginsenosides from Panax ginseng and shows various bioactivities. Although it has also been found to have the property of anti-diabetes, the long-term effect of CK on insulin secretion in β-cells is still unclear. In this study, CK was prepared from ginsenoside Rd by snailase hydrolysis and its effect on the insulin secretion activity in MIN6 pancreatic β-cell lines in vitro was assessed. The expression of glucose transporter isoform-2 (GLUT2) and the cellular ATP content were also examined by western blot and HPLC analysis, respectively. The results showed that CK significantly enhanced insulin secretion, increased cellular ATP content, and upregulated the expression of GLUT2. These findings indicate that CK exerts prominent stimulatory effects on insulin secretion in the MIN6 cells partly via upregulating the expression of GLUT2.
Collapse
Affiliation(s)
- Jian Gu
- Department of Pharmacology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Ahmad Z, Rasouli M, Azman AZF, Omar AR. Evaluation of insulin expression and secretion in genetically engineered gut K and L-cells. BMC Biotechnol 2012; 12:64. [PMID: 22989329 PMCID: PMC3469342 DOI: 10.1186/1472-6750-12-64] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2012] [Accepted: 09/17/2012] [Indexed: 12/25/2022] Open
Abstract
Background Gene therapy could provide an effective treatment of diabetes. Previous studies have investigated the potential for several cell and tissue types to produce mature and active insulin. Gut K and L-cells could be potential candidate hosts for gene therapy because of their special features. Results In this study, we isolated gut K and L-cells to compare the potential of both cell types to produce insulin when exposed to similar conditions. The isolated pure K and L-cells were transfected with recombinant plasmids encoding insulin and with specific promoters for K or L-cells. Insulin expression was studied in response to glucose or meat hydrolysate. We found that glucose and meat hydrolysate efficiently induced insulin secretion from K and L-cells. However, the effects of meat hydrolysate on insulin secretion were more potent in both cells compared with glucose. Results of enzyme-linked immunosorbent assays showed that L-cells secreted more insulin compared with K-cells regardless of the stimulator, although this difference was not statistically significant. Conclusion The responses of K and L-cells to stimulation with glucose or meat hydrolysate were generally comparable. Therefore, both K and L-cells show similar potential to be used as surrogate cells for insulin gene expression in vitro. The potential use of these cells for diabetic gene therapy warrants further investigation.
Collapse
Affiliation(s)
- Zalinah Ahmad
- Laboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, UPM Serdang, Selangor 43400, Malaysia.
| | | | | | | |
Collapse
|
5
|
Polakof S, Mommsen TP, Soengas JL. Glucosensing and glucose homeostasis: from fish to mammals. Comp Biochem Physiol B Biochem Mol Biol 2011; 160:123-49. [PMID: 21871969 DOI: 10.1016/j.cbpb.2011.07.006] [Citation(s) in RCA: 205] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2011] [Revised: 07/20/2011] [Accepted: 07/22/2011] [Indexed: 12/16/2022]
Abstract
This review is focused on two topics related to glucose in vertebrates. In a first section devoted to glucose homeostasis we describe how glucose levels fluctuate and are regulated in different classes of vertebrates. The detection of these fluctuations is essential for homeostasis and for other physiological processes such as regulation of food intake. The capacity of that detection is known as glucosensing, and the different mechanisms through which it occurs are known as glucosensors. Different glucosensor mechanisms have been demonstrated in different tissues and organs of rodents and humans whereas the information obtained for other vertebrates is scarce. In the second section of the review we describe the present knowledge regarding glucosensor mechanisms in different groups of vertebrates, with special emphasis in fish.
Collapse
Affiliation(s)
- Sergio Polakof
- INRA, UMR, UNH, CRNH Auvergne, Clermont-Ferrand, France.
| | | | | |
Collapse
|
6
|
Gammell P, O'Driscoll L, Clynes M. Characterisation of BHK-21 cells engineered to secrete human insulin. Cytotechnology 2011; 41:11-21. [PMID: 19002958 DOI: 10.1023/a:1024296220592] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Autoimmune destruction of beta cells in the pancreas leads to type I, or insulin dependent diabetes mellitus (IDDM), through the loss of endogenous insulin production capacity. This paper describes an attempt to generate 'artificial'beta cells using the fibroblast cell line BHK21. Stable transfectants expressing the human preproinsulin (PPI) gene were isolated and characterised. The resulting clone selected for further analysis (BHK-PPI-C16) was capable of secreting 0.12 pmol proinsulin/hr/10(5) cells and maintained a steady cellular proinsulin content of 0.36 +/- 0.04 pmol l(-1). There was no processing of the proinsulin to mature insulin. The cells were unresponsive to glucose but there was increased proinsulin secretion in the presence of agents that stimulated formation of intracellular cAMP. Transfection of cDNAs for the key elements of the glucose sensing apparatus (GLUT2 and glucokinase) led to a subphysiological stimulation of secretion when glucokinase was transfected alone while there was a complete loss of insulin secretion when both components were overexpressed. The deleterious effect on proinsulin secretion observed upon co-expression of the glucose sensing genes may have implications for applications requiring multigene expression in BHK21 cells.
Collapse
Affiliation(s)
- Patrick Gammell
- National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
| | | | | |
Collapse
|
7
|
Bara H, Sambanis A. Insulin-secreting L-cells for the treatment of insulin-dependent diabetes. Biochem Biophys Res Commun 2008; 371:39-43. [PMID: 18406351 DOI: 10.1016/j.bbrc.2008.03.154] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2008] [Accepted: 03/27/2008] [Indexed: 11/24/2022]
Abstract
Cell-based treatments for insulin-dependent diabetes (IDD) may provide more physiologic regulation of blood glucose levels than daily insulin injections, thereby reducing the occurrence of secondary complications associated with diabetes. An autologous cell source is especially attractive for regulatory and ethical reasons in addition to eliminating the need for immunosuppression. This study uses non-beta-cells, genetically modified for physiologic insulin secretion. Enteroendocrine L-cells, exhibit regulated secretion in response to physiologic stimuli and their endogenous products are fully compatible with prandial metabolism. Murine GLUTag L-cells were transfected with a plasmid co-expressing human insulin and neomycin resistance and the stable cell line, GLUTag-INS, was established. Secretion properties of GLUTag-INS cells were investigated in vitro through induced secretion tests using meat hydrolysate or 3-isobutyl-1-methylxanthine and forskolin as secretagogues. GLUTag-INS cells rapidly co-secreted recombinant insulin and endogenous glucagon-like peptide in response to metabolic cues from the surrounding medium and demonstrated efficient processing of proinsulin to insulin.
Collapse
Affiliation(s)
- Heather Bara
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, 315 Ferst Drive, IBB Building, Room 1306, Atlanta, GA 30332, USA
| | | |
Collapse
|
8
|
Polakof S, Míguez JM, Soengas JL. In vitro evidences for glucosensing capacity and mechanisms in hypothalamus, hindbrain, and Brockmann bodies of rainbow trout. Am J Physiol Regul Integr Comp Physiol 2007; 293:R1410-20. [PMID: 17567722 DOI: 10.1152/ajpregu.00283.2007] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
We aimed to support in vitro the glucosensing capacity observed in vivo in rainbow trout hypothalamus, hindbrain, and Brockmann bodies (BB) and to obtain preliminary evidence of the mechanisms involved. The response of parameters involved in the glucosensing capacity [hexokinase, hexokinase IV (glucokinase), and pyruvate kinase activities and glucose and glycogen levels] was assessed in these tissues incubated for 1 h with 2, 4, or 8 mM d-glucose alone (control) or with specific agonists/inhibitors of the steps involved in glucosensing capacity in mammals. These agents were a competitor for glucose phosphorylation (15 mM mannose), sulfonylurea receptor-1 effectors (500 μM tolbutamide or diazoxide), glycolytic intermediates (15 mM glycerol, lactate, or pyruvate), and inhibitors of glucose transport (10 μM cytochalasin B), glycolysis [20 mM 2-deoxy-d-glucose (2-DG)], and L-type calcium channel (1 μM nifedipine). Control incubations of the three tissues displayed increased glucose and glycogen levels and glucokinase activities in response to increased medium glucose, thus supporting our previous in vivo studies. Furthermore, critical components of the glucosensing mammalian machinery are apparently functioning in the three tissues. The responses in brain regions to all substances tested (except 2-DG and nifedipine) were similar to those observed in mammals, suggesting a similar glucosensing machinery. In contrast, in BB, only the effects of 2-DG, lactate, pyruvate, diazoxide, and nifedipine were similar to those of mammalian β-cells, suggesting that some of the components of the piscine glucosensing model are different than those of mammals. Such differences may relate to the importance of amino acids rather than glucose signaling in the trout BB.
Collapse
Affiliation(s)
- Sergio Polakof
- Laboratorio de Fisioloxía Animal, Facultade de Bioloxía, Edificio de Ciencias Experimentais, Universidade de Vigo, E-36310 Vigo, Spain
| | | | | |
Collapse
|
9
|
Chistiakov DA, Tyurina I. Current strategies and perspectives in insulin gene therapy for diabetes. Expert Rev Endocrinol Metab 2007; 2:27-34. [PMID: 30743746 DOI: 10.1586/17446651.2.1.27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Insulin gene therapy is an approach that might overcome the weakness of islet cell therapy owing to its vulnerability to autoimmune attack. There are several mandatory conditions for successful insulin gene therapy. Efficient insulin gene therapy should have an effective insulin gene delivery mechanism, a system of regulation of the insulin biosynthesis that responds to glucose within extremely narrow physiological limits, a system of insulin processing into its active form and a choice of appropriate target cells, which possess biochemical characteristics similar to β cells, but are not targets for β-cell-specific self-reactivity. In this article, advantages and disadvantages of non-β-cell types that are most likely to be used for generating surrogate insulin-producing β cells are compared. Current achievements in insulin gene therapy are critically evaluated and future challenges are discussed.
Collapse
Affiliation(s)
- Dimitry A Chistiakov
- a Assistant Professor, University of Pittsburgh Medical Center, Department of Pathology, 3550 Terrace Street, Pittsburgh, PA, 15261, USA.
| | - Inna Tyurina
- b Executive Manager and Consultant, Public Relations and Consulting Group 'Imya', 8th Tekstilschikov Street 11, 109129, Moscow, Russia.
| |
Collapse
|
10
|
Bain JR, Hoffman AS. Tissue-culture surfaces with mixtures of aminated and fluorinated functional groups. Part 2. Growth and function of transgenic rat insulinoma cells (betaG I/17). JOURNAL OF BIOMATERIALS SCIENCE. POLYMER EDITION 2004; 14:341-67. [PMID: 12747674 DOI: 10.1163/156856203321478865] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Interactions of transplantable cells with synthetic polymers can influence the function of biohybrid artificial organs. This study explored growth and secretion of human insulin by betaG I/17 cells cultured on surfaces bearing diamine groups (N2), trifluoropropyl groups (F3) and mixtures of the two. Cells cultured on high-F3 and high-N2 surfaces spread well, grew rapidly and produced >1.8 mol lactate per mol glucose consumed, closely resembling cells grown on the permissive control, glass. On one mixed surface, with a molar ratio of 33 N2 groups:67 F3 groups, cells had a lower lactate/glucose ratio, adopted a rounded form, grew slowly and were quick to form emergent aggregates, similar to cultures on the inhibitory control, untreated polystyrene. Cultures on surfaces with higher F3 content secreted the most insulin and, in the case of the highest-F3 surface, showed improved responsiveness to secretagogues. Hormone secretion was roughly 50% greater when cells were grown on F3 surfaces conditioned by earlier cultures of betaG I/17. Incubation of conditioned surfaces with high concentrations of a polyclonal anti-laminin serum prior to re-plating partially abolished this improvement in secretory function. Polymers bearing trifluoropropyl groups appear to be attractive candidates for use in the artificial endocrine pancreas. Surface coatings that include laminin might promote function of transgenic insulinoma cells in vitro and in vivo.
Collapse
Affiliation(s)
- James R Bain
- Sarah W. Stedman Center for Nutritional Studies, Duke University Medical Center, Durham, NC 27710, USA.
| | | |
Collapse
|
11
|
Abstract
The field of metabolic engineering encompasses a powerful set of tools that can be divided into (a) methods to model complex metabolic pathways and (b) techniques to manipulate these pathways for a desired metabolic outcome. These tools have recently seen increased utility in the medical arena, and this paper aims to review significant accomplishments made using these approaches. The modeling of metabolic pathways has been applied to better understand disease-state physiology in a variety of cellar, subcellular, and organ systems, including the liver, heart, mitochondria, and cancerous cells. Metabolic pathway engineering has been used to generate cells with novel biochemical functions for therapeutic use, and specific examples are provided in the areas of glycosylation engineering and dopamine-replacement therapy. In order to document the potential of applying both metabolic modeling and pathway manipulation, we describe pertinent advances in the field of diabetes research. Undoubtedly, as the field of metabolic engineering matures and is applied to a wider array of problems, new advances and therapeutic strategies will follow.
Collapse
Affiliation(s)
- Martin L Yarmush
- Center for Engineering in Medicine/Surgical Services, Massachusetts General Hospital, Shriners Burns Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
| | | |
Collapse
|
12
|
Tang SC, Sambanis A. Development of genetically engineered human intestinal cells for regulated insulin secretion using rAAV-mediated gene transfer. Biochem Biophys Res Commun 2003; 303:645-52. [PMID: 12659868 DOI: 10.1016/s0006-291x(03)00399-1] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cell-based therapies for treating insulin-dependent diabetes (IDD) can provide a more physiologic regulation of blood glucose levels in a less invasive fashion than daily insulin injections. Promising cells include intestinal enteroendocrine cells genetically engineered to secrete insulin in response to physiologic stimuli; responsiveness occurs at the exocytosis level to regulate the acute release of recombinant insulin. In this work, we established a human cellular model to demonstrate that meat hydrolysate can simultaneously stimulate glucagon-like peptide-1 (GLP-1, an enteroendocrine cell-derived incretin hormone) and recombinant insulin secretion from the engineered human NCI-H716 intestinal cell line. Cells were genetically modified using the recombinant adeno-associated virus (rAAV)-mediated insulin gene transfer. Recombinant cells were then differentiated to display endocrine features, in particular the formation of granule-like compartments. A fusion protein of insulin and enhanced green fluorescence protein (EGFP) was designed to reveal the compartments of localization of the fusion protein and assess its co-localization with endogenous GLP-1. Our work provides a unique human cellular model for regulated insulin release through genetic engineering of GLP-1-secreting intestinal cells, which is expected to be useful for cell-based therapies of IDD.
Collapse
Affiliation(s)
- Shiue-Cheng Tang
- School of Chemical Engineering, Georgia Tech-Emory Center for the Engineering of Living Tissues, and P.H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | | |
Collapse
|
13
|
Osamura RY, Kumaki N, Kajiwara H, Egashira N, Miyai S, Takekoshi S, Yasuda M, Umemura S. Endocrine pathology in translational medicine: an overview of current and future prospects. Endocr Pathol 2003; 14:117-21. [PMID: 12858001 DOI: 10.1385/ep:14:2:117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
With applications of recent development of molecular techniques, endocrine pathology, as a scientific discipline, has been expanding its field to cover not only the pathologic diagnosis but also molecular mechanisms of hormone production and secretion as well as implementation for appropriate therapeutic approaches. In this review, the discussion includes molecular markers for the diagnosis of neuroendocrine (NE) tumors focusing on various proteins for the transport of secretory granules. MIB-1, proliferative indices, is particularly useful to access biologic activities of NE tumors. The specific hormone production relies on the expression of combination of transcription factors and proteolytic digestion (processing) of prohormones by specific enzymes, prohormone convertases PC1/3 and PC2. Inappropriate processing of prohormones sometimes are related to neoplastic conditions. Endocrine therapeutics have been focusing on the compensation of deficient hormones by transplanting specific hormone producing cells including embryonic stem (ES) cells. The endocrine pathology is expected to play a major role in translational medicine.
Collapse
Affiliation(s)
- Robert Yoshiyuki Osamura
- Department of Pathology, Tokai University School of Medicine, Boseidai Isehara-city, Kanagawa, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Kojima H, Nakamura T, Fujita Y, Kishi A, Fujimiya M, Yamada S, Kudo M, Nishio Y, Maegawa H, Haneda M, Yasuda H, Kojima I, Seno M, Wong NCW, Kikkawa R, Kashiwagi A. Combined expression of pancreatic duodenal homeobox 1 and islet factor 1 induces immature enterocytes to produce insulin. Diabetes 2002; 51:1398-408. [PMID: 11978636 DOI: 10.2337/diabetes.51.5.1398] [Citation(s) in RCA: 106] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Immature rat intestinal stem cells (IEC-6) given the ability to express the transcription factor, pancreatic duodenal homeobox 1 (Pdx-1), yielded YK cells. Although these cells produced multiple enteroendocrine hormones, they did not produce insulin. Exposure of YK cells to 2 nmol/l betacellulin yielded BYK cells that showed the presence of insulin expression in cytoplasm and that secreted insulin into culture media. By examining the mechanism of differentiation in BYK cells, we found that another transcription factor, islet factor 1 (Isl-1) was newly expressed with the disappearance of Pax-6 expression in those cells after exposure to betacellulin. These results indicated that combined expression of Pdx-1 and Isl-1 in IEC-6 cells was required for the production of insulin. In fact, overexpression of both Pdx-1 and Isl-1 in IEC-6 cells (Isl-YK-12, -14, and -15 cells) gave them the ability to express insulin without exposure to betacellulin. Furthermore, implantation of the Isl-YK-14 cells into diabetic rats reduced the animals' plasma glucose levels; glucose levels dropped from 19.4 to 16.9 mmol/l 1 day after the injection of cells. As expected, the plasma insulin concentrations were 2.7 times higher in the diabetic rats injected with Isl-YK-14 cells compared to in controls. In summary, our results indicated that immature intestinal stem cells can differentiate into insulin-producing cells given the ability to express the transcription factors Pdx-1 and Isl-1.
Collapse
Affiliation(s)
- Hideto Kojima
- Third Department of Medicine, Shiga University of Medical Science, Shiga, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Qin XY, Shen KT, Zhang X, Cheng ZH, Xu XR, Han ZG. Establishment of an artificial β-cell line expressing insulin under the control of doxycycline. World J Gastroenterol 2002; 8:367-70. [PMID: 11925627 PMCID: PMC4658386 DOI: 10.3748/wjg.v8.i2.367] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: Artificial β-cell lines may offer an abundant source of cells for the treatment of type I diabetes, but insulin secretion in β-cells is tightly regulated in physiological conditions. The Tet-On system is a “gene switch” system, which can induce gene expression by administration of tetracycline (Tet) derivatives such as doxcycline (Dox). Using this system, we established 293 cells to an artificial cell line secreting insulin in response to stimulation by Dox.
METHODS: The mutated proinsulin cDNA was obtained from plasmid pcDNA3.1/C-mINS by the polymerase chain reaction (PCR), and was inserted downstream from the promoter on the expression vector pTRE2, to construct a recombined expression vector pTRE2mINS. The promoter on pTRE2 consists of the tetracycline-response element and the CMV minimal promoter and is thus activated by the reverse tetracycline-controlled transactivator (rtTA) when Dox is administrated. pTRE2mINS and plasmid pTK-Hyg encoding hygromycin were co-transfected in the tet293 cells, which express rtTA stably. Following hygromycin screening, the survived cells expressing insulin were selected and enriched. Dox was used to control the expression of insulin in these cells. At the levels of mRNA and protein, the regulating effect of Dox in culture medium on the expression of proinsulin gene was estimated respectively with Northern blot, RT-PCR, and radioimmunoassay.
RESULTS: From the 28 hygromycin-resistant cell strains, we selected one cell strain (tet293/Ins6) secreting insulin not only automatically, but in response to stimulation by Dox. The amount on insulin secretion was dependent on the Dox dose (0, 10, 100, 200, 400, 800 and 1000 μg•L⁻¹), the level of insulin secreted by the cells treated with Dox (1000 μg·L-1) was 241.0 pU·d-1× cell-1, which was 25-fold that of 9.7 pU·d-1× cell-1 without Dox treatment. Northern blot analyses and RT-PCR further confirmed that the transcription of insulin gene had already been up-regulated after exposing tet293/Ins6 cells to Dox for 15 min, and was also induced in a dose-dependent manner. However, the concentration of insulin in the media did not increase significantly until 5 h following the addition of Dox.
CONCLUSION: Human proinsulin gene was transfected successfully and expressed efficiently in 293 cells, and the expression was modulated by tetracycline and its derivatives, improving the accuracy, safety, and reliability of gene therapy, suggesting that conditional establishment of artificial β-cells may be a useful approach to develop cellular therapy for diabetes mellitus.
Collapse
Affiliation(s)
- Xin-Yu Qin
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
| | | | | | | | | | | |
Collapse
|
16
|
Faradji RN, Havari E, Chen Q, Gray J, Tornheim K, Corkey BE, Mulligan RC, Lipes MA. Glucose-induced toxicity in insulin-producing pituitary cells that coexpress GLUT2 and glucokinase. Implications for metabolic engineering. J Biol Chem 2001; 276:36695-702. [PMID: 11443115 DOI: 10.1074/jbc.m102542200] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We have shown that intermediate lobe (IL) pituitary cells can be engineered to produce sufficient amounts of insulin (ins) to cure diabetes in nonobese diabetic mice but, unlike transplanted islets, ILins cells evade immune attack. To confer glucose-sensing capabilities into these cells, they were further modified with recombinant adenoviruses to express high levels of GLUT2 and the beta-cell isoform of glucokinase (GK). Although expression of GLUT2 alone had negligible effects on glucose usage and lactate production, expression of GK alone resulted in approximately 2-fold increase in glycolytic flux within the physiological (3-20 mm) glucose range. GLUT2/GK coexpression further increased glycolytic flux at 20 mm glucose but disproportionately increased flux at 3 mm glucose. Despite enhanced glycolytic fluxes, GLUT2/GK-coexpressing cells showed glucose dose-dependent accumulation of hexose phosphates, depletion of intracellular ATP, and severe apoptotic cell death. These studies demonstrate that glucose-sensing properties can be introduced into non-islet cells by the single expression of GK and that glucose responsiveness can be augmented by the coexpression of GLUT2. However, in the metabolic engineering of surrogate beta cells, it is critical that the levels of the components be closely optimized to ensure their physiological function and to avoid the deleterious consequences of glucose-induced toxicity.
Collapse
Affiliation(s)
- R N Faradji
- Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Berná G, León-Quinto T, Fuentes E, Andreu E, Nadal A, Roche E, Martín F, Reig JA, Soria B. [Cellular engineering and diabetes mellitus]. Rev Clin Esp 2001; 201:548-56. [PMID: 11692416 DOI: 10.1016/s0014-2565(01)70908-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- G Berná
- Instituto de Bioingeniería, Universidad Miguel Hernández de Elche. Alicante, 03550 San Juan, Alicante.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Chen R, Meseck M, McEvoy RC, Woo SL. Glucose-stimulated and self-limiting insulin production by glucose 6-phosphatase promoter driven insulin expression in hepatoma cells. Gene Ther 2000; 7:1802-9. [PMID: 11110411 DOI: 10.1038/sj.gt.3301306] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The liver is an attractive target organ for insulin gene expression in type 1 diabetes as it contains appropriate cellular mechanisms of regulated gene expression in response to blood glucose and insulin. We hypothesize that insulin production regulated by both glucose and insulin may be achieved using the promoter of the glucose 6-phosphatase gene (G6Pase), the expression of which in the liver is induced by glucose and suppressed by insulin. Recombinant adenoviral vectors expressing the reporter gene CAT or insulin under transcriptional direction of the G6Pase promoter were constructed. Glucose-stimulated as well as self-limiting insulin production was achieved in vector-transduced hepatoma cells in which expression of the insulin gene was controlled by the G6Pase promoter. While insulin strongly inhibited the G6Pase promoter activity under low glucose conditions, its inhibitory capacity was attenuated when glucose levels were elevated. At the physiologic glucose level of 5.5 mM glucose, vector-transduced hepatoma cells produced a self-limited level of insulin at approximately 0.2-0.3 ng/ml, which is within the range of fasting levels of insulin in normal animals. These results indicate that the G6Pase promoter possesses desirable features and may be developed for regulated hepatic insulin gene expression in type 1 diabetes.
Collapse
Affiliation(s)
- R Chen
- Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
| | | | | | | |
Collapse
|
19
|
Yamasaki K, Sasaki T, Nemoto M, Eto Y, Tajima N. Differentiation-induced insulin secretion from nonendocrine cells with engineered human proinsulin cDNA. Biochem Biophys Res Commun 1999; 265:361-5. [PMID: 10558872 DOI: 10.1006/bbrc.1999.1698] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
To investigate the effects of differentiation on insulin secretion from engineered nonendocrine cells, modified human proinsulin cDNA (INS/fur) was transfected to THP-1 monocyte and C2C12 myoblast cell lines. When THP-1 was differentiated into macrophages with phorbol ester, the insulin secretion rate was increased by 3.1-fold. This increase in insulin secretion is accompanied by a 17.6-fold increase in the processing efficiency of the modified human proinsulin and by a 3.5-fold increase in the abundance of furin mRNA. In addition, differentiation of C2C12 into myotubes, which can be induced by changing the serum, showed a 9.9-fold increase in insulin secretion and was accompanied by a 1.6-fold increase in the abundance of furin mRNA. The involvement of posttranslational processing and the exocytotic process in differentiation-induced insulin secretion could lead to the possibility of regulation of insulin secretion from genetically engineered cells.
Collapse
Affiliation(s)
- K Yamasaki
- Department of Internal Medicine (III), Jikei University School of Medicine
| | | | | | | | | |
Collapse
|